Heavy! Pfizer new crown oral medicine "amazing effect", COVID-19 will be terminated?

在世界上第一种新型皇冠口服药物molnupiravir宣布在英国上市后的一天，辉瑞发出了另一个沉重的消息。辉瑞公司开发的新冠口服药物帕克洛维德的临床试验"令人惊讶"，高危患者住院和死亡的风险降低了89%。许多业内人士直言不讳地说："随着新冠口服药的到来，新冠的全球流行形势有望结束。"

One day after molnupiravir, the world's first new crown oral drug, was announced to be on the market in the UK, Pfizer sent another heavy news. The clinical trial of paxlovid, the new crown oral drug developed by Pfizer, was "amazing", and the risk of hospitalization and death of high-risk patients decreased by 89%. Many people in the industry said bluntly: "with the arrival of new crown oral drugs, the world pandemic situation of new crown is expected to end."

随着新关口服药的到来，世界范围内的新关疫情有望结束

With the arrival of Xinguan oral medicine, the world pandemic situation of Xinguan is expected to end

辉瑞新冠口服药的疗效有多"惊人"？

How "amazing" is the efficacy of Pfizer Xinguan oral medicine?

在任何药物上市之前，都必须经过严格的临床试验，而新型关口药帕克洛维德（paxlovid）的II/III期临床试验结果让人们大开眼界。

Before any drug goes on the market, it has to go through strict clinical trials, and the results of phase II / III clinical trials of paxlovid, a new Guankou drug, brighten people's eyes.

关口新药帕克洛维德（paxlovid）的II/III期临床试验结果让人们大开眼界

The results of the phase II / III clinical trial of paxlovid, a new Guankou drug, brightened people's eyes

在这项名为epic hr的研究中，paxlovid分别用于3天和5天内出现新冠相关症状的患者。最终结果如下：

In this study called epic-hr, paxlovid was used in patients with new crown related symptoms within 3 days and 5 days respectively. The final results are as follows:

● 3天内出现新冠相关症状的患者

● patients with new crown related symptoms within 3 days

与安慰剂组（对照组）相比，paxlovid患者因新冠导致的住院率和死亡风险降低了89%，paxlovid后28天内的住院率仅为0.8%（3/389），而无paxlovid的对照组28天内的住院率为7%（27/385），27人中有7人死亡。整个实验的p值小于0.0001。

Compared with the placebo group (control group), the hospitalization rate and death risk of patients with paxlovid due to the new crown decreased by 89%, and the hospitalization rate within 28 days after paxlovid was only 0.8% (3 / 389), while the hospitalization rate within 28 days in the control group without paxlovid was 7% (27 / 385), and 7 of 27 died. The p value of the whole experiment was less than 0.0001.

● 5天内出现新冠相关症状的患者

● patients with new crown related symptoms within 5 days

与安慰剂组（对照组）相比，paxlovid患者因新冠导致的住院率和死亡风险降低了85%，paxlovid后28天内的住院率仅为1%（6/607），而无paxlovid的对照组28天内的住院率为6.7%（41/612），41人中有10人死亡。整个实验的p值小于0.0001。

Compared with the placebo group (control group), the hospitalization rate and risk of death of patients with paxlovid due to new crown decreased by 85%, and the hospitalization rate within 28 days after paxlovid was only 1% (6 / 607), while the hospitalization rate within 28 days in the control group without paxlovid was 6.7% (41 / 612), and 10 of 41 died. The p value of the whole experiment was less than 0.0001.

"惊人的"帕克洛维德与传统的对抗新皇冠的方法有何不同？

How is the "amazing" paxlovid different from the traditional method of fighting the new crown?

自从新冠病毒出现以来，人们花费了大量时间研究其结构特征和感染复制。一方面，我们可以更多地了解新冠病毒-19，另一方面，我们可以通过了解病毒的复制来加速新冠药物的研发。

Since the advent of COVID-19, people have spent a lot of time studying its structural characteristics and infection replication. On the one hand, we can learn more about COVID-19, and on the other hand, we can accelerate the research and development of new crown drugs by understanding the replication of viruses.

作为一种冠状病毒，新冠病毒与传统冠状病毒没有区别。它是最简单的遗传物质RNA和蛋白质外壳。由于该病毒只能"寄生"在宿主体内，在宿主细胞核糖体的帮助下转化为所需的蛋白质，所以新冠病毒-19只是一种单链RNA病毒。

As a coronavirus, COVID-19 has no difference from traditional coronavirus. It is the simplest genetic material RNA and protein shell. Because the virus can only "parasite" in the host body, with the help of the ribosome of the host cell to translate into the protein it needs, COVID-19 is a just single strand RNA virus.

新冠病毒-19进入细胞复制和感染的过程也非常简单。一般来说，可分为三个步骤：

The process of COVID-19 entering cell replication and infection is also very simple. In general, it can be divided into three steps:

● 首先，病毒表面的棘突蛋白（s蛋白）与细胞膜上的ACE2受体结合，细胞入口敞开，病毒进入细胞。

● first, the spike protein (s protein) on the virus surface binds to the ACE2 receptor on the cell membrane, the cell portal is wide open, and the virus enters the cell.

● 其次，在宿主细胞核糖体的帮助下，RNA被翻译成两个长的多聚蛋白质，然后需要一种特殊的水解酶（3CL蛋白酶）来切割多聚蛋白质，形成病毒所需的蛋白质和酶。

● secondly, the RNA is translated into two long poly proteins with the help of the ribosome of the host cell, and then a special hydrolase (3CL protease) is required to cut the poly protein to form the proteins and enzymes required by the virus.

● 最后，它在RNA依赖性RNA聚合酶（RdRp）的作用下复制形成新的RNA，然后与水解酶水解的蛋白质结合，最终形成大量新病毒并继续感染新细胞。

● finally, it replicates under the action of an RNA dependent RNA polymerase (RdRp) to form new RNA, then binds to the protein hydrolyzed by hydrolase, finally forms a large number of new viruses and continues to infect new cells.

特殊的水解酶（3CL蛋白酶）切割多聚蛋白，形成病毒所需的蛋白质和酶

The special hydrolase (3CL protease) cuts the poly protein to form the protein and enzyme required by the virus

现在我们了解了病毒复制和感染的过程，我们的研发主要集中在上述三个步骤上。例如，新冠疫苗的研发主要集中在第一步的spike蛋白和ACE2受体的结合，而著名的redcivir主要集中在第三步的RNA依赖性RNA聚合酶（RdRp），而paxlovid主要集中在第二步的水解酶（3CL蛋白酶）。通过抑制水解酶，多蛋白不能被水解，有效地阻止了新冠病毒-19的复制。

Now that we understand the process of virus replication and infection, our research and development mainly focuses on the above three steps. For example, the research and development of new crown vaccine mainly focuses on the combination of spike protein and ACE2 receptor in the first step, while the well-known redcivir mainly focuses on the RNA dependent RNA polymerase (RdRp) in the third step, and this paxlovid mainly focuses on the hydrolase in the second step (3CL protease). By inhibiting hydrolases, polyprotein can not be hydrolyzed, effectively blocking the replication of COVID-19.

新皇冠医学的出现是否意味着疫苗不再重要？

Does the advent of the new crown medicine mean that the vaccine is no longer important?

随着新冠口服药临床试验数据的揭晓，许多人表现出非常乐观的态度。一些人认为，帕克洛维德的出现将大大降低新冠感染的严重程度，甚至促进疫情的结束。有些人甚至放弃接种疫苗，等待新的皇冠口服药。

With the Unblinding of the clinical trial data of Xinguan oral drug, many people show a very optimistic attitude. Some people think that the advent of paxlovid will greatly reduce the severity of new crown infection and even promote the end of the epidemic. Some even give up vaccination and wait for new crown oral medicine.

Link：https://new.qq.com/omn/20211106/20211106A0AFJ500.html

update time：2021-11-07 18:16:53